Why the study?
The therapeutic impact of targeting branched-chain amino acid catabolic flux under pathological conditions remained understudied.
Does BT2 improve cardiac function and structure in mice with pressure-overload induced heart failure?
Does BT2 improve cardiac function and structure in mice with pressure-overload induced heart failure?
Targeting BCAA catabolic flux with BT2 provides proof-of-concept evidence for preserving cardiac function in preexisting heart failure.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating in mouse pressure-overload; leaves open clinical translation of BCAA catabolism enhancement in human HF.
Background Branched-chain amino acid (BCAA) catabolic defect is an emerging metabolic hallmark in failing hearts in human and animal models. The therapeutic impact of targeting BCAA catabolic flux under pathological conditions remains understudied. Methods and Results BT2 (3,6-dichlorobenzo[b]thiophene-2-carboxylic acid), a small-molecule inhibitor of branched-chain ketoacid dehydrogenase kinase, was used to enhance BCAA catabolism. After 2 weeks of transaortic constriction, mice with significant cardiac dysfunctions were treated with vehicle or BT2. Serial echocardiograms showed continuing pathological deterioration in left ventricle of the vehicle-treated mice, whereas the BT2-treated mice showed significantly preserved cardiac function and structure. Moreover, BT2 treatment improved systolic contractility and diastolic mechanics. These therapeutic benefits appeared to be independent of impacts on left ventricle hypertrophy but associated with increased gene expression involved in fatty acid utilization. The BT2 administration showed no signs of apparent toxicity. Conclusions Our data provide the first proof-of-concept evidence for the therapeutic efficacy of restoring BCAA catabolic flux in hearts with preexisting dysfunctions. The BCAA catabolic pathway represents a novel and potentially efficacious target for treatment of heart failure.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2019) studied Pressure-overload induced heart failure. BT2 (3,6-dichlorobenzo[b]thiophene-2-carboxylic acid) vs. Vehicle was evaluated on Cardiac function and structure.
Synapse has enriched 10 related papers. Consider them for comparative context: